Drug Delivery Business

New medicines could eliminate uterine fibroid surgeries

By

[Image from the U.S. Department of Health and Human Services]
Decisions Resources Group, a healthcare research and data company, suggests that the launch of new medicines could be a long-term management alternative to uterine fibroids surgeries over the next 10 years.

Novel selective progesterone receptor modulators (SPRMs) like Allergan/Gedeon Richter’s ulipristal, Bayer’s vilaprisan and Repros’s Proellex – and gonadotropin-releasing hormone (Gn-RH) antagonists like AbbVie’s elagolix, Myovant’s relugolix and ObsEva’s OBE-2109 – are projected to be effective medical alternatives to surgical procedures. Hysterectomies and myomectomies are the current long-term management of uterine fibroids.

Get the full story on our sister site, Medical Design & Outsourcing.

IN CASE YOU MISSED IT

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].